Immunotherapy combo shows promise for rare cancers, but study halted early
NCT ID NCT02938793
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested a combination of two immunotherapy drugs, durvalumab and tremelimumab, in 92 people with advanced rare solid tumors who had no other standard treatment options. The goal was to see if the drugs could shrink tumors and to check for side effects. The study was terminated early, so the full results are not available, but the approach aims to harness the immune system to fight these uncommon cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab and tremelimumab (immunotherapy drugs)
What this could lead to
If it works, this could point toward a new treatment option for people with rare cancers that have few standard therapies.
What could go wrong
This was a small, early-phase study that was terminated, so results are limited. Immunotherapy can cause serious immune-related side effects, and not all rare tumors respond to these drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Greenville Health System Cancer Institute
Greenville, South Carolina, 29605, United States